



VALIDATION DATA

1. Introduction

Olink® Inflammation is a reagent kit measuring 92 inflammation related human protein biomarkers simultaneously. The analytical performance of the product has been carefully validated and the results are presented below.

1.1 TECHNOLOGY

The Olink reagents are based on the Proximity Extension Assay (PEA) technology^{1,2}, where 92 oligonucleotide labeled antibody probe pairs are allowed to bind to their respective target protein present in the sample. A PCR reporter sequence is formed by a proximity dependent DNA polymerization event, amplified, and subsequently detected and quantified using real-time PCR. The assay is performed in a homogeneous 96-well format without any need for washing steps, see Figure 1.

1.2 QUALITY CONTROLS

Internal and external controls have been developed by Olink for data normalization and quality control purposes. These controls have been designed to enable monitoring of the technical assay performance, as well as the quality of individual samples, providing information at each step of the Olink protocol (see Figure 1). The internal controls are added to each sample and include two Immunoassay controls, one Extension control and one Detection control. The Immunoassay controls (two non-human proteins) monitor all three steps starting with the immunoreaction. The Extension Control (an antibody linked to two matched oligonucleotides for immediate proximity independent of antigen binding) monitors the extension and readout steps and is used for data

normalization across samples. Finally, the Detection control (a synthetic double-stranded template) monitors the readout step. Samples for which one or more of the internal control values deviate from a pre-determined range will be flagged and may be removed before statistical analysis.


An external control, inter-plate control (IPC), is included on each plate and used in a second normalization step. This control is made up of a pool of probes similar to the Extension control (Ext Ctrl), but generated with 92 matching oligonucleotide pairs. Furthermore, the improves inter-assay precision and allows for optimal comparison of data derived from multiple runs. The term “Normalized Protein eXpression (NPX)” refers to normalized data as described above.

1.3 DATA ANALYSIS

Data analysis was performed by employing a pre-processing normalization procedure. For each sample and data point, the corresponding Cq-value for the Extension control was subtracted, thus normalizing for technical variation within one run. Normalization between runs is then performed for each assay by subtracting the corresponding dCq-value for the Interplate Control (IPC) from the dCq-values generated. In the final step of the pre-processing procedure the values are set relative to a correction factor determined by Olink. The generated Normalized Protein eXpression (NPX) unit is on a log2 scale where a larger number represents a higher protein level in the sample, typically with the background level at around zero. Linearization of data is performed by the mathematical operation 2^{NPX} . Coefficient of variation (CV) calculations were performed on linearized values.


IMMUNOASSAY

Allow the 92 antibody probe pairs to bind to their respective proteins in your samples.




EXTENSION

Extend and pre-amplify 92 unique DNA reporter sequences by proximity extension.



DETECTION

Quantify each biomarker's DNA reporter using high throughput real-time qPCR.



Immunoassay control

Extension control

Detection control

Fig 1. Olink assay procedure (above) and controls (below). The internal controls enables monitoring of the three core steps in the Olink assay and used for quality control and data normalization. Read out is performed by using the Fluidigm® Biomark™ or the Fluidigm® Biomark™ HD system.

2. Performance characteristics

2.1 SAMPLE TYPES

The ability to use different sample types was evaluated with the Olink Inflammation I^{96x96} by collecting matched serum, EDTA, acid citrate dextrose (ACD), and sodium heparin plasma samples from 5 individuals. Response values observed between heparin, citrate plasma or serum, are expressed as relative differences (%) compared to EDTA plasma and shown in Table 1 for each sample type. To evaluate the measuring range of endogenous protein levels, response values levels were assessed in 22 normal EDTA plasma samples and reported in NPX, Table 1.

Variations observed between responses in heparin and citrate plasma, as compared to EDTA plasma, were generally small, and most of the assays will therefore function without limitation in these sample types. Serum gives a higher signal compared to EDTA plasma for several assays. The results indicate that all plasma types and serum are suitable for the Olink Inflammation I^{96x96} panel, but citrate and heparin plasma have not been fully validated.

2.2 ANALYTICAL MEASUREMENT

DETECTION LIMIT

Calibrator curves were determined for 90 out of 92 biomarkers simultaneously in a multiplex format. One protein biomarker lacked accessible recombinant antigens (4E-BP1). Limit of detection (LOD) was defined as 3 standard deviations above background, and reported in pg/mL, see Table 1.

HIGH DOSE HOOK EFFECT

The high dose hook effect is a state of antigen excess relative to the reagent antibodies, resulting in falsely lower values. In such cases, a significantly lower value can be reported which leads to misinterpretation of results. Therefore, the hook effect was determined for each analyte, here reported in pg/mL, see Table 1.

MEASURING RANGES

The analytical measuring range was defined by the lower limit of quantification (LLOQ) and upper limit of quantification (ULOQ) and reported in pg/mL. Quantification limits of LLOQ and ULOQ were calculated with the following trueness and precision criteria; relative error $\leq 30\%$ and CV $\leq 30\%$, of back-calculated values, respectively. Measuring ranges were reported in order of log₁₀, see Table 1.

Representative assays with their analytical data are exemplified in Figure 2 and the distribution of

measuring ranges of 90 assay is shown in Figure 3. Separate calibrator curves established for each assay may be viewed at www.olink.com.




Fig 2. Calibrator curves for representative assays and analytical data using a 4-parameter curve fitting model.




Fig 3. Distribution of analytical measuring range, defined by the limits of quantification LLOQ-ULOQ, for 90 out of 92 analytes.

Table 1. Sample Types; acid citrate dextrose (ACD), ethylenediaminetetraacetic acid (EDTA), sodium heparin (heparin) and serum, Analytical Measurement; Limit of Detection (LOD), Lower/Upper Limit of Quantification (LLOQ/ULOQ), High Dose Effect (Hook), Range and Precision indicative of assay performance are shown for 92 analytes. Values below LOD were not reported (NR). Endogenous interference was performed by addition of hemolysate (Hemo), lipids and bilirubin (Bili) in serum and EDTA plasma matrix. Reported are the highest tested concentrations without impact on assay performance in either serum or EDTA plasma.

Target	UniProt No	Sample types				Analytical measurement				Precision		Endogenous interference						
		Signal-to-background (2^{NPX})				Relative 2^{NPX} to EDTA				pg/mL		log10		g/L	mg/mL	µg/mL		
		ACD	EDTA	Heparin	Serum	ACD	Heparin	Serum	LOD	LLOQ	ULOQ	Hook	Range	Intra	Inter	Hemo	Lipids	Bili
Adenosine Deaminase (ADA)	P00813	45	58	47	58	77%	80%	99%	0.48	0.48	31250	125000	4.8	5%	29%	15	20	630
Artemin (ARTN)	Q5T4W7	NR	1	NR	1	NR	NR	102%	0.24	0.48	31250	62500	4.8	7%	18%	15	20	630
Axin-1 (AXIN1)	O15169	4	9	3	4	50%	30%	42%	61	61	62500	250000	3.0	6%	19%	15	20	630
Beta-nerve growth factor (Beta-NGF)	P01138	3	3	2	4	95%	81%	123%	0.48	0.48	15625	31250	4.5	6%	14%	15	20	630
Brain-derived neurotrophic factor (BDNF)	P23560	16	21	16	23	75%	76%	109%						6%	10%	15	20	630
Caspase 8 (CASP-8)	Q14790	3	3	3	5	84%	105%	154%	0.48	0.48	31250	62500	4.8	7%	22%	15	20	630
C-C motif chemokine 4 (CCL4)	P13236	37	68	56	99	55%	82%	146%	1.9	1.9	31250	62500	4.2	6%	17%	7.5	20	315
C-C motif chemokine 19 (CCL19)	Q99731	1014	1128	870	1249	90%	77%	111%	15	15	31250	62500	3.3	8%	15%	7.5	20	315
C-C motif chemokine 20 (CCL20)	P78556	169	184	132	139	91%	72%	75%	7.6	7.6	15625	15625	3.3	7%	13%	15	20	158
C-C motif chemokine 23 (CCL23)	P55773	322	384	313	358	84%	81%	93%	31	31	31250	62500	3.0	6%	13%	15	20	315
C-C motif chemokine 25 (CCL25)	O15444	71	82	73	95	86%	89%	115%	3.8	3.8	62500	125000	4.2	6%	18%	15	10	158
C-C motif chemokine 28 (CCL28)	Q9NRJ3	3	4	2	4	75%	60%	111%	61	122	1000000	1000000	3.9	7%	14%	15	20	630
CD40L receptor (CD40)	P25942	399	463	452	646	86%	98%	140%	0.01	0.01	3906	15625	5.4	5%	21%	15	20	630
CUB domain-containing protein 1 (CDCP1)	Q9H5V8	7	8	7	9	81%	87%	107%	0.12	0.12	7812	31250	4.8	6%	24%	7.5	10	315
C-X-C motif chemokine 1 (CXCL1)	P09341	135	422	713	1301	32%	169%	308%	3.8	7.6	15625	15625	3.3	6%	15%	15	10	79
C-X-C motif chemokine 5 (CXCL5)	P42830	336	3011	5114	9171	11%	170%	305%	0.95	0.95	7812	15625	3.9	7%	13%	15	10	315
C-X-C motif chemokine 6 (CXCL6)	P80162	50	177	409	840	28%	231%	475%	7.6	31	15625	31250	2.7	8%	14%	15	20	315
C-X-C motif chemokine 9 (CXCL9)	Q07325	54	68	59	68	80%	87%	100%	0.95	0.95	3906	7812	3.6	6%	12%	15	20	315
C-X-C motif chemokine 10 (CXCL10)	P02778	378	505	378	546	75%	75%	108%	7.6	7.6	15625	31250	3.3	7%	11%	15	20	315
C-X-C motif chemokine 11 (CXCL11)	O14625	94	308	578	850	31%	188%	276%	7.6	31	15625	15625	2.7	7%	14%	15	20	158
Cystatin D (CST5)	P28325	86	97	89	101	88%	91%	104%	1.9	1.9	15625	31250	3.9	5%	21%	15	20	315
Delta and Notch-like epidermal growth factor-related recep (DNER)	Q8NFT8	181	201	181	220	90%	90%	109%	0.95	1.9	31250	62500	4.2	5%	26%	15	20	630
Eotaxin-1 (CCL11)	P51671	247	294	307	318	84%	104%	108%	3.8	3.8	31250	62500	3.9	5%	14%	15	20	630
Eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1)	Q13541	14	102	12	61	14%	12%	59%						6%	23%	15	10	158
Fibroblast growth factor 5 (FGF-5)	Q8NF90	2	2	2	2	90%	76%	104%	1.9	1.9	31250	125000	4.2	7%	14%	15	20	630
Fibroblast growth factor 19 (FGF-19)	Q95750	387	477	394	503	81%	83%	105%	7.6	7.6	15625	31250	3.3	6%	19%	15	20	315
Fibroblast growth factor 21 (FGF-21)	Q9NSA1	30	39	35	35	76%	89%	89%	31	31	62500	500000	3.3	8%	21%	3.8	5	158
Fibroblast growth factor 23 (FGF-23)	Q9GZV9	27	38	33	9	71%	86%	22%	122	122	62500	62500	2.7	9%	26%	7.5	10	315
Fms-related tyrosine kinase 3 ligand (Flt3L)	P49771	405	493	410	532	82%	83%	108%	0.01	0.01	977	3906	4.8	6%	15%	15	10	315
Fractalkine (CX3CL1)	P78423	58	70	64	101	84%	92%	145%	15.3	15.3	15625	31250	3.0	7%	24%	15	20	630
Glial cell line-derived neurotrophic factor (hGDNF)	P39905	5	5	3	4	92%	51%	85%	0.01	0.01	1953	3906	5.1	7%	12%	15	20	630
Hepatocyte growth factor (HGF)	P14210	85	130	67	198	66%	52%	153%	7.6	7.6	125000	125000	3.9	6%	16%	7.5	10	315
Interferon gamma (IFN-gamma)	P01579	2	2	2	2	104%	89%	103%	15.3	15.3	62500	62500	3.6	7%	17%	15	20	630
Interleukin-1 alpha (IL-1 alpha)	P01583	NR	NR	3	2	NR	NR	NR	0.48	0.95	31250	125000	4.5	7%	18%	15	20	630
Interleukin-2 (IL-2)	P60568	NR	NR	NR	2	NR	NR	NR	30.5	30.5	1000000	1000000	4.5	9%	16%	15	20	630
Interleukin-2 receptor subunit beta (IL-2RB)	P14784	NR	2	2	2	NR	96%	101%	15	31	250000	1000000	3.9	7%	19%	15	20	630
Interleukin-4 (IL-4)	P05112	NR	2	NR	2	NR	NR	115%	0.24	0.24	7812	15625	4.5	7%	16%	15	20	630
Interleukin-5 (IL-5)	P05113	4	2	3	2	175%	126%	105%	3.8	3.8	15625	62500	3.6	7%	17%	15	20	630
Interleukin-6 (IL-6)	P05231	28	31	31	40	90%	99%	128%	0.12	0.12	3906	15625	4.5	6%	8%	15	20	315
Interleukin-7 (IL-7)	P13232	3	7	4	19	45%	64%	283%	0.24	0.24	7812	15625	4.5	6%	18%	15	20	315
Interleukin-8 (IL-8)	P10145	41	69	73	129	60%	106%	188%	0.03	0.03	3906	7812	5.1	6%	15%	15	20	79
Interleukin-10 (IL-10)	P22301	7	10	8	10	75%	77%	105%	0.48	0.48	62500	125000	5.1	7%	12%	15	20	630
Interleukin-10 receptor subunit alpha (IL-10RA)	Q13651	3	2	2	2	137%	94%	105%	3.8	7.6	250000	500000	4.5	6%	19%	15	20	630
Interleukin-10 receptor subunit beta (IL-10RB)	Q08334	61	75	71	79	81%	95%	105%	0.12	0.12	1953	3906	4.2	5%	31%	7.5	20	630
Interleukin-12 subunit beta (IL-12B)	P29460	12	14	10	16	87%	74%	111%	0.12	0.12	3906	3906	4.5	6%	16%	15	20	630
Interleukin-13 (IL-13)	P35225	NR	NR	NR	NR	NR	NR	NR	7.6	7.6	62500	500000	3.9	14%	26%	15	20	630

		Sample types				Analytical measurement				Precision		Endogenous interference						
Target	UniProt No	Signal-to-background (2 ^{NPX})				Relative 2 ^{NPX} to EDTA			pg/mL		log10		Intra	Inter	g/L	mg/mL	µg/mL	
		ACD	EDTA	Heparin	Serum	ACD	Heparin	Serum	LOD	LLOQ	ULOQ	Hook			Range	Hemo	Lipids	Bili
Interleukin-15 receptor subunit alpha (IL-15RA)	Q13261	2	2	2	2	93%	84%	112%	0.95	0.95	7812	15625	3.9	6%	20%	15	20	630
Interleukin-17A (IL-17A)	Q16552	NR	2	2	2	NR	93%	109%	3.8	7.6	62500	62500	3.9	8%	17%	15	20	630
Interleukin-17C (IL-17C)	Q9P0M4	4	5	4	5	81%	81%	110%	31	31	125000	500000	3.3	8%	18%	15	20	630
Interleukin-18 (IL-18)	Q14116	124	153	133	164	81%	87%	108%	0.06	0.06	15625	15625	5.4	6%	19%	15	10	315
Interleukin-18 receptor 1 (IL-18R1)	Q13478	93	115	102	132	81%	89%	115%	0.06	0.06	7812	15625	5.1	5%	26%	15	20	630
Interleukin-20 (IL-20)	Q9NYY1	2	2	1	2	97%	79%	103%	7.6	15	62500	125000	3.6	7%	22%	15	20	630
Interleukin-20 receptor subunit alpha (IL-20RA)	Q9UHF4	NR	2	NR	2	NR	NR	99%	1.9	1.9	125000	125000	4.8	6%	22%	15	20	630
Interleukin-22 receptor subunit alpha-1 (IL-22 RA1)	Q8N6P7	NR	4	3	3	NR	79%	87%	0.24	0.24	3906	15625	4.2	7%	23%	15	20	630
Interleukin-24 (IL-24)	Q13007	NR	2	2	2	NR	116%	108%	1.9	3.8	31250	125000	3.9	6%	29%	15	20	630
Interleukin-33 (IL-33)	Q95760	NR	2	NR	2	NR	NR	97%	3.8	3.8	31250	125000	3.9	9%	26%	15	20	630
Latency-associated peptide transforming growth factor beta 1 (LAP TGF-beta-1)	P01137	81	183	190	352	44%	104%	192%	61	61	500000	500000	3.9	7%	24%	7.5	20	315
Leukemia inhibitory factor (LIF)	P15018	48	38	60	22	126%	158%	57%	3.8	7.6	15625	31250	3.3	7%	18%	15	20	630
Leukemia inhibitory factor receptor (LIF-R)	P42702	6	8	7	9	75%	83%	107%	30.5	15.3	62500	250000	3.3	7%	26%	15	20	630
Macrophage colony-stimulating factor 1 (CSF-1)	P09603	235	264	227	297	89%	86%	113%	0.004	0.01	1953	3906	5.4	5%	25%	15	20	630
Macrophage inflammatory protein 1-alpha (MIP-1 alpha)	P10147	5	7	5	9	71%	74%	129%	0.06	0.06	488	977	3.9	6%	14%	15	20	315
Matrix metalloproteinase-1 (MMP-1)	P03956	3	9	6	9	28%	68%	93%	1.9	3.8	15625	31250	3.6	5%	19%	15	20	630
Matrix metalloproteinase-10 (MMP-10)	P09238	104	103	117	145	101%	114%	141%	0.95	0.95	15625	62500	4.2	5%	28%	15	20	315
Monocyte chemoattractant protein 1 (MCP-1)	P13500	1064	1213	1063	1494	88%	88%	123%	0.03	0.03	1953	3906	4.8	6%	13%	15	20	315
Monocyte chemoattractant protein 2 (MCP-2)	P80075	363	610	488	982	60%	80%	161%	0.06	0.06	3906	7812	4.8	6%	8%	15	20	315
Monocyte chemoattractant protein 3 (MCP-3)	P80098	4	5	6	6	78%	110%	120%	0.48	0.48	1953	3906	3.6	7%	17%	15	20	315
Monocyte chemoattractant protein 4 (MCP-4)	Q99616	5	8	9	15	59%	111%	189%	7.6	7.6	3906	3906	2.7	6%	11%	15	20	315
Natural killer cell receptor 2B4 (CD244)	Q9BZW8	60	75	67	81	81%	90%	108%	0.06	0.06	7812	15625	5.1	5%	24%	15	20	630
Neurotrophin-3 (NT-3)	P20783	4	5	2	4	75%	37%	78%	0.12	0.12	3906	7812	4.5	6%	13%	15	20	630
Neurturin (NRTN)	Q99748	NR	2	NR	2	NR	NR	109%	3.8	7.6	15625	62500	3.3	9%	15%	15	20	630
Oncostatin-M (OSM)	P13725	6	14	12	37	46%	86%	272%	0.03	0.03	977	3906	4.5	5%	12%	15	20	79
Osteoprotegerin (OPG)	O00300	1205	1385	1103	1520	87%	80%	110%	0.24	0.48	31250	62500	4.8	6%	12%	15	20	315
Programmed cell death 1 ligand 1 (PD-L1)	Q9NZQ7	6	5	5	6	135%	99%	124%	3.8	3.8	500000	1000000	5.1	9%	25%	15	20	630
Protein S100-A12 (EN-RAGE)	P80511	8	4	12	35	196%	274%	825%	122	122	500000	1000000	3.6	8%	17%	15	20	630
Signaling lymphocytic activation molecule (SLAMF1)	Q13291	6	7	6	8	82%	89%	113%	31	31	1000000	1000000	4.5	9%	21%	15	20	630
SIR2-like protein 2 (SIRT2)	Q8IXJ6	8	36	8	20	23%	21%	57%	7.6	15.3	62500	250000	3.6	8%	22%	15	20	630
STAM-binding protein (STAMPB)	Q95630	10	25	9	17	39%	37%	67%	7.6	7.6	31250	62500	3.6	5%	27%	15	20	630
Stem cell factor (SCF)	P21583	334	368	356	418	91%	97%	113%	1.9	3.8	15625	31250	4	5%	20%	15	20	630
Sulfotransferase 1A1 (ST1A1)	P50225	3	2	5	5	122%	228%	193%	244	244	125000	500000	2.7	6%	25%	1.88	20	630
T-cell surface glycoprotein CD5 (CD5)	P06127	21	23	20	24	90%	89%	104%	0.06	0.12	3906	15625	4.5	5%	22%	15	20	630
T cell surface glycoprotein CD6 isoform (CD6)	Q8WWJ7	19	23	21	22	84%	91%	98%	0.24	0.24	7812	31250	4.2	6%	23%	15	20	630
Thymic stromal lymphopoietin (TSLP)	Q969D9	NR	2	NR	2	NR	NR	94%	3.8	3.8	15625	62500	3.6	6%	20%	15	20	630
TNF-beta (TNFB)	P01374	13	14	13	16	93%	91%	114%	0.24	0.48	15625	15625	4.5	6%	22%	15	20	630
TNF-related activation-induced cytokine (TRANCE)	O14788	23	27	23	29	83%	84%	106%	3.8	3.8	31250	125000	3.9	7%	24%	15	20	630
TNF-related apoptosis-inducing ligand (TRAIL)	P50591	383	425	382	484	90%	90%	114%	0.95	0.95	31250	31250	4.5	5%	17%	15	20	630
Transforming growth factor alpha (TGF-alpha)	P01135	3	3	3	11	90%	81%	342%	0.48	0.48	3906	31250	3.9	6%	27%	15	20	158
Tumor necrosis factor (Ligand) superfamily member 12 (TWEAK)	Q4ACW9	410	537	432	669	76%	80%	124%	1.9	1.9	125000	500000	4.8	6%	11%	15	20	315
Tumor necrosis factor (TNF)	P01375	8	5	7	7	177%	158%	153%	0.48	0.48	3906	15625	3.9	9%	11%	15	20	630
Tumor necrosis factor ligand superfamily member 14 (TNFSF14)	Q43557	5	6	7	23	74%	119%	376%	0.95	1.9	15625	31250	3.9	6%	15%	15	20	315
Tumor necrosis factor receptor superfamily member 9 (TNFRSF9)	Q07011	74	84	76	95	88%	91%	114%	0.03	0.03	3906	3906	5.1	5%	21%	15	20	315
Urokinase-type plasminogen activator (uPA)	P00749	1227	1408	1306	1346	87%	93%	96%	0.12	0.12	7812	15625	4.8	5%	11%	7.5	20	315
Vascular endothelial growth factor A (VEGF-A)	P15692	1218	1909	1608	3004	64%	84%	157%	0.06	0.06	7812	15625	5.1	6%	8%	15	20	630

2.3 PRECISION

REPEATABILITY

Intra-assay variation (within-run) was calculated as the mean CV for 7 individual samples, within each of 10 separate runs during the validation studies. Inter-assay variation (between-run) was calculated as the mean CV, for the same 7 individual samples, between 6 separate runs during the validation studies. Variation calculations were assessed on linearized values for all 92 analytes, see Table 1.

Across all 92 assays, the mean intra-assay and inter-assay variations were observed to be 7% and 18%, respectively. The distribution of both intra-assay and inter-assay variations is shown in Figure 4.




Fig 4. Distribution of intra-assay and inter-assay variations of Olink Inflammation I ^{96x96}

REPRODUCIBILITY

Inter-site variation (between-site) was also investigated during the validation in a β -site study, to estimate the expected variations in values between different laboratories, with different operators and using different equipment. Seven individual samples were distributed to each of 2 sites together with Olink Inflammation I ^{96x96} reagent kits. Each site was instructed to perform the analysis of the 7 individual samples according to the same run design. Each site was also asked to perform two independent runs.

The overall design of the β -site study enabled the estimation of intra-assay and inter-assay variations for 3 sites including Olink Proteomics, and the inter-site variation for each site, here shown in Figure 5.

The mean CV for intra-assay analysis ranged from 5% to 12%. The mean CV ranged from 11% to 21% inter-assay, and 11% to 13% inter-site, here shown in direct comparison to Olink Proteomics in Figure 5.

Overall, the Olink Inflammation I ^{96x96} showed very

good reproducibility and repeatability with average inter-site CV of 17%.




Fig 5. Validation of the Olink Inflammation I ^{96x96} at 2 ($\beta 1$ - $\beta 2$) different laboratories. Larger boxes show intra-assay and inter-assay variations for each site and small boxes represent the inter-site run variations in direct comparison to Olink Proteomics.

2.4 ANALYTICAL SPECIFICITY

ENDOGENOUS INTERFERENCE

Endogenous interference from heterophilic antibodies, e.g. human anti-mouse antibody (HAMA), and rheumatoid factor are known to cause problems in immunoassays. To evaluate the potential impact of this specific interference, a special "mismatch" system was designed. The only way to generate a signal in this system is by antibody probe pairs being brought into proximity, by cross-binding substances other than antigens, e.g. heterophilic antibodies and similarly acting rheumatoid factor. A total of 69 different "mismatched" probe pairs of varying host species origin were designed and evaluated with samples from Heterophilic Assessment panel from Scantibodies laboratory Inc. (part. No. 3KG027) with HAMA concentration (<3-3641 ng/ml) and another set of samples known to contain rheumatoid factor (<20-1190 IU/ml). No interference interpreted as signal above LOD due to HAMA or RF disturbances could be detected for any of the samples, indicating a sufficient blocking ability in all assays in the Olink Inflammation I ^{96x96} (data not shown).

The potential impact of certain known interfering serum and plasma components was evaluated by using serial dilutions of hemolysate, lipids and bilirubin, respectively in EDTA plasma and serum, as shown in Figure 6. These additions represent different patient health conditions and/or sample collection irregularities. Table 1 lists the highest concentration of each interfering substance without impact on assay performance. In 10 out of 92 assays altered expression was observed by the addition of hemolysate. The reason is most likely due to actual analyte leaking out of the disrupted blood cells. A concentration of 15 g/L of hemolysate represents 10% hemolysis of a sample. Also, in 10 assays interference was observed by addition of lipids ≥ 5 mg/mL, which would correspond to very high serum triglyceride levels³. Addition of bilirubin altered 37 out of 92 assays at ≥ 79 $\mu\text{g/mL}$, which is more than 4 times the normal total bilirubin levels⁴.




Fig 6. Endogenous interference. Levels tested for hemolysate were 0.23 - 15 g/L hemoglobin, lipids 0.3 - 20 mg/mL and bilirubin 10 - 630 $\mu\text{g/mL}$. The highest hemolysate concentration translates to about 10% hemolysis.

2.5 SCALABILITY

Assay performance was further evaluated with regard to scalability, meaning the capability of the Olink technology to maintain the same quality of performance irrespective of multiplex grade. A step-wise increase of multiplex grade (24, 48, 72 and 96) was performed and the observed dCq values for the 24-plex were plotted against the 48-plex, 72-plex and 96-plex for each analyte. The correlation coefficient R^2 value generated by linear regression analysis reflects

the correlation between the multiplex assays. The R^2 values were >0.99 for the different multiplex blocks, as shown in Figure 7, demonstrating the scalability of the system.




Fig 7. Scalability of the Olink technology platform. This experiment was performed using the Olink Oncology I 96×96 panel. Human serum samples were analyzed with a 24-plex, 48-plex and 72-plex assay and the complete Proseek Multiplex Oncology I 96×96 panel. The observed dCq (log2) values were plotted, and the correlation coefficient R^2 value was generated by linear regression.

3. References

1. Assarsson E, Lundberg M, Holmquist G, Björkesten J, Bucht Thorsen S, Ekman D, Eriksson A, Rennel Dickens E, Ohlsson S, Edfeldt G, Andersson AC, Lindstedt P, Stenvang J, Gullberg M, Fredriksson S. Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability. *PLoS One* April (2014). doi: 10.1371/journal.pone.0095192.
2. Lundberg M, Eriksson A, Tran B, Assarsson E, Fredriksson S. Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low abundant proteins in human blood. *Nucleic Acid Res* June (2011). doi: 10.1093/nar/gkr424.
3. <http://emedicine.medscape.com/article/2074115-overview>
4. <http://www.nlm.nih.gov/medlineplus/ency/article/003479.htm>

TECHNICAL SUPPORT

For technical support, please contact us at support@olink.com or +46 18 444 3970

For Research Use Only. Not for Use in Diagnostic Procedures.

This product includes a license for non-commercial use of Olink products. Commercial users may require additional licenses. Please contact Olink Proteomics AB for details.

There are no warranties, expressed or implied, which extend beyond this description. Olink Proteomics AB is not liable for property damage, personal injury, or economic loss caused by this product.

The following trademarks are owned by Olink AB: Olink® and Olink Bioscience™.

This product is covered by several patents and patent applications including US 6,511,809, US 7,306,904 and related US and foreign patents.

This product is sold under license from PHRI Properties, Inc. and may be used under PHRI Properties patent rights outside the field of human in vitro diagnostics.

Components in the Olink Probe Kit utilise Lightning-Link™ technology and are provided under license from Innova Biosciences.

© Copyright 2018 Olink Proteomics AB. All third party trademarks are the property of their respective owners.

0993, v2.0, 2018-03-16

Olink Proteomics
Dag Hammarskjölds v. 52B
SE-752 37 Uppsala, Sweden
www.olink.com